251 filings
Page 4 of 13
8-K
w3r6z37em7a8fn
11 Oct 22
Regulation FD Disclosure
7:36am
8-K
0lf5r7xoexx8
19 Aug 22
Other Events
5:42pm
S-8
aiy5b edzhgdlr7b5
15 Aug 22
Registration of securities for employees
8:32pm
8-K
73r2cywms7 me79
24 Jun 22
Submission of Matters to a Vote of Security Holders
5:01pm
DEFA14A
cxwejc s7q
5 May 22
Additional proxy soliciting materials
8:31am
8-K
z7th3h55
5 May 22
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
8:30am
DEFA14A
9ioxhmgq6tbty jf
28 Apr 22
Additional proxy soliciting materials
4:29pm
8-K
d54m6x6kh1hnv5pwy
27 Apr 22
Regulation FD Disclosure
4:13pm
8-K
1vpq4ft
31 Mar 22
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial
7:06am
8-K
40k 01bcrgmh
2 Mar 22
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of
8:00am
8-K
ogf3s9m2vky
8 Feb 22
Departure of Directors or Certain Officers
4:23pm
8-K
rtedy
4 Jan 22
Other Events
8:08am
8-K
a2f87rx
3 Jan 22
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy
8:08am
8-K
vgqw5dhyyw3kwti
17 Nov 21
Other Events
7:30am